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Epstein-Barr virus (EBV) is a ubiquitous human 
herpesvirus that infects >90% of the population. 
Primary EBV infection is generally asymptom-
atic;  however,  when  the  infection  is  delayed 
until adolescence or later, 50% of cases mani-
fest as infectious mononucleosis (IM). IM is 
characterized by the expansion of reactive   
T cells and is most likely to be an immunopatho-
logic disease whose general symptoms are caused 
by proinflammatory cytokines, such as IL-1, 
IFN-, and TNF (Rickinson and Kieff, 2001). 
Chronic active EBV infection (CAEBV) and 
EBV-associated hemophagocytic lymphohis-
tiocytosis (EBV-HLH) are also active EBV in-
fections with persistent or recurrent IM-like 
symptoms. EBV-HLH is characterized by an 
EBV infection in T cells and the systemic release 
of proinflammatory cytokines, which subse-
quently causes hemophagocytosis of blood cells 
through the activation of macrophages (Kikuta 
et al., 1993; Rickinson and Kieff, 2001).
The EBV noncoding RNAs, EBV-encoded 
RNA 1 (EBER1) and EBER2, are 167 and 
172 nt long, respectively, and are expected to 
form dsRNA-like structures (Rosa et al., 1981). 
EBER is the most abundant viral transcript in 
latently EBV-infected cells (Rymo, 1979), and 
binds to several cellular proteins including 
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Epstein-Barr virus–encoded small RNA (EBER) is nonpolyadenylated, noncoding RNA that 
forms stem-loop structure by intermolecular base-pairing, giving rise to double-stranded 
RNA (dsRNA)–like molecules, and exists abundantly in EBV-infected cells. Here, we report 
that EBER induces signaling from the Toll-like receptor 3 (TLR3), which is a sensor of viral 
double-stranded RNA (dsRNA) and induces type I IFN and proinflammatory cytokines.  
A substantial amount of EBER, which was sufficient to induce signaling from TLR3, was 
released from EBV-infected cells, and the majority of the released EBER existed as a com-
plex with a cellular EBER-binding protein La, suggesting that EBER was released from the 
cells by active secretion of La. Sera from patients with infectious mononucleosis (IM), 
chronic active EBV infection (CAEBV), and EBV-associated hemophagocytic lymphohistiocy-
tosis (EBV-HLH), whose general symptoms are caused by proinflammatory cytokines con-
tained EBER, and addition of RNA purified from the sera into culture medium induced 
signaling from TLR3 in EBV-transformed lymphocytes and peripheral mononuclear cells. 
Furthermore, DCs treated with EBER showed mature phenotype and antigen presentation 
capacity. These findings suggest that EBER, which is released from EBV-infected cells, is 
responsible for immune activation by EBV, inducing type I IFN and proinflammatory cyto-
kines. EBER-induced activation of innate immunity would account for immunopathologic 
diseases caused by active EBV infection.
© 2009 Iwakiri et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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EBER1 induces signaling from TLR3
To investigate the role of the EBER1 that was released from 
EBV-infected  cells,  we  first  examined  whether  in  vitro–ﾭ 
synthesized EBER1 could induce signaling from TLR3. 
RT-PCR assays indicated that LCLs and gastric carcinoma–ﾭ
derived NU-GC-3 cells (Akiyama et al., 1988) expressed TLR3 
(Fig. 2 A).The addition of in vitro–ﾭsynthesized EBER1 into 
culture medium induced IFN- in LCLs and EBV-positive 
and -negative NU-GC-3 cells (Fig. 2 B; Imai et al., 1998). A 
similar result was also obtained by the TLR3 agonist poly(I:C). 
An ELISA indicated that IFN- production was dependent on 
the amount of EBER1 that was added to the culture superna-
tants; we found that 0.1 ng/ml EBER1 was sufficient to in-
duce the release of IFN- (Fig. 2 C). Next, we evaluated the 
efficiency of EBER1 to induce IFN- expression in LCLs 
comparing with poly(I:C). No difference in efficiency was ob-
served between EBER1 and poly(I:C) by RT-PCR (Fig. 2 D).
When LCLs were pretreated with an anti-TLR3 anti-
body (Matsumoto et al., 2002), and then treated with EBER1, 
the effect of EBER1 on the induction of IFN- was mark-
edly reduced (Fig. 2 E). In addition, TLR3 knockdown by 
siRNA resulted in reduced induction of IFN (Fig. 2 F), indi-
cating that EBER1 induces IFN through TLR3. IFN-regu-
latory factor 3 (IRF3) and NF-B function downstream of 
the TLR3 signaling pathway (Akira and Takeda, 2004). As 
shown in Fig. 2 G, both IRF3 and NF-B were phosphory-
lated upon treatment of the cells with EBER1 or poly(I:C).
We next examined whether the EBER1 that was released 
into culture supernatants could induce the expression of IFN. 
Cell culture supernatant was harvested on day 4 and added to 
the culture medium of LCLs. After 14 h of cultivation, the 
induction of IFN- in LCLs was determined by RT-PCR. 
The results indicated that IFN was induced in EBV-positive 
cells, but not in EBV-negative cells or EBER-knockout 
EBV-infected cells (Fig. 2 H).
EBER1 is detected as a complex with La in the culture 
supernatants, and the complex can induce TLR3 signaling
The stable presence of EBER1 in culture supernatants sug-
gested that EBER1 was bound by some proteins, thus being 
protected from degradation by nucleases. We then examined 
whether the EBER1 that was present in culture supernatants 
existed as a complex with EBER-binding cellular proteins. 
Flag-tagged L22, La, and PKR were transfected into Mutu+ 
cells, and their interaction with EBER1 in culture super-
natants was examined by coimmunoprecipitation assays. Al-
though flag-tagged L22, La, and PKR were expressed equally 
in transfected cells, only La could be strongly immunopre-
cipitated from the culture supernatant (Fig. 3 A). RT-PCR 
indicated that EBER1 preferentially coimmunoprecipitated 
with La (Fig. 3 B). The presence of La in culture supernatants 
suggested that La was actively secreted from living cells rather 
than passively released from dead cells. These results indicate 
that EBER1 was released from EBV-infected cells as a com-
plex with La. To further assess whether EBER can activate 
TLR3 in complexes with La, we used immunoprecipitates 
RNA-activated protein kinase (PKR; Clarke et al., 1991), 
ribosomal protein 22 (L22; Toczyski et al., 1994), lupus ery-
thematosis–ﾭassociated antigen (La; Lerner et al., 1981), and 
retinoic acid–ﾭinducible gene I (RIG-I; Samanta et al., 2006).
Here, we report that EBER exists in the sera of patients 
with active EBV infections and induces type I IFN and in-
flammatory cytokines through TLR3-mediated signaling. 
This may account for the pathogenesis of active EBV infec-
tions that are characterized by cytokinemia.
RESULTS AND DISCUSSION
EBER is present in the culture supernatants  
of EBV-infected cells
RT-PCR assays have revealed that EBER is present in the 
culture supernatants of the Burkitt’s lymphoma–ﾭderived EBV-
positive cell lines Mutu+ (Gregory et al., 1990) and Akata+ 
(Takada, 1984), and the EBV-transformed lymphoblastoid 
cell lines (LCLs). EBER was detected on day 1 of the cul-
ture, and its expression peaked on day 4 (Fig. 1 A). In a 
real-time PCR assay, 15–ﾭ35 ng/ml EBER1 was released 
into the culture supernatants, whereas EBER2 was only 
faintly detected (Fig. 1 B).
Figure 1.  EBER1 is released into the culture supernatants of EBV-
infected Mutu+, Akata+ and LCL. (A) RT-PCR of EBER1. Cells (2 × 105 
cells/ml) were cultured for the designated number of days. Total RNA was 
extracted from 1 ml culture supernatant and subjected to 25 cycles of 
RT-PCR to detect EBER1. Three or more independent experiments were per-
formed. (B) Quantitative RT-PCR of EBER1 and EBER2. Cells (2 × 105) were 
cultured in 1 ml medium for 4 d, and total RNA was extracted from the 
culture supernatant and subjected to RT-RCR for the detection of EBER1 
and EBER2. Error bars indicate the SD of duplicate wells. The data pre-
sented are representative of three independent experiments.JEM VOL. 206, September 28, 2009  2093
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Figure 2.  EBER1 activates signaling through TLR3. (A) Detection of TLR3 in three LCL clones and EBV-infected and uninfected NU-GC-3 cells. Total RNA 
(0.1 µg) was subjected to 30 cycles of RT-PCR to detect TLR3. RT-PCR for GAPDH was used as an internal control. Three or more independent experiments were 
performed for each assay. (B) Effect of in vitro–synthesized EBER1 on the expression of IFN-. LCLs and EBV-positive and –negative NU-GC-3 cells were treated 
with 0.5 µg/ml in vitro–synthesized EBER1 or poly(I:C) and were cultured for 14 h. Total RNA (0.1 µg) was subjected to 30 cycles of RT-PCR to detect IFN-. 
RT-PCR for GAPDH was used as an internal control. Three or more independent experiments were performed. (C) Dose response of the effect of in vitro–synthesized 
EBER1 on the expression of IFN-. LCLs (4 × 105 cells/ml) were treated with 0.1–1,000 ng/ml EBER1 and cultured for 14 h. IFN- in culture supernatants was 
quantified by ELISA. Error bars indicate the S.D. of duplicate wells. The data presented are representative of three independent experiments. (D) Efficiency of 
EBER1 and poly(I:C) to induce IFN- expression in LCLs. LCLs (4 × 105 cells/ml) were treated with 1–1,000 ng/ml EBER1 and cultured for 14 h. IFN- induction 
was analyzed by RT-PCR. Three or more independent experiments were performed for each assay. (E) Effect of an anti-TLR3 antibody on EBER1-induced IFN- 
production. LCLs were preincubated with the anti-TLR3 antibody for 30 min at 37°C, before being treated with 0.5 µg/ml of EBER1 and incubated for 14 h. The 
culture was analyzed for IFN- induction by RT-PCR (upper panel) and ELISA (lower panel). Error bars indicate the SD of duplicate wells. The data presented are 
representative of three independent experiments. (F) Effect of TLR3 knockdown on EBER1-induced IFN- production. Negative control siRNA (nc) or TLR3-
siRNA (TLR) were transfected into EBER-knockout EBV-infected AGS cells. After 48 h, cells were treated with EBER1 or poly(I:C) and IFN- induction was ana-
lyzed by RT-PCR (bottom). Efficiency of TLR3 silencing was analyzed by RT-PCR (top). Three or more independent experiments were performed for each assay. 
(E) Effect of EBER1 on the downstream signals of TLR3, IRF3, and NF-B. LCLs were treated with 2.5 µg/ml in vitro–synthesized EBER1 or poly(I:C) and cultured 
for 3 h before the phosphorylation of IRF3, and NF-B was examined by immunoblotting using antibodies against phosphorylated IRF3, total IRF3, and phos-
phorylated p65. The data presented are representative of three independent experiments. (F) Effect of culture supernatants from EBER-positive cells on the 
expression of IFN-. The study includes EBV-positive and –negative Mutu cells, EBV-positive and –negative Akata cells, and EBV-negative Akata cells that were 
stably infected with EBER-positive EBV or EBER-knockout EBV. The cells (2 × 105 cells/ml) were cultured for 4 d and then the culture supernatants were har-
vested. LCLs (4 × 105) were treated with 1 ml culture supernatants (top) or RNA extracted from 1 ml culture supernatants in 1 ml culture medium (bottom) for 
14 h. RNA (0.1 µg) was subjected to 30 cycles of RT-PCR to detect IFN-. Three or more independent experiments were performed for each assay.2094 TLR3 ACTIVATION BY EBV- ENCODED SMALL RNA | Iwakiri et al.
the sera from healthy individuals (Fig. 4 A); however, the 
level of EBER1 was much higher in patient sera than that 
obtained from healthy individuals. Our real-time PCR assays 
indicated that the sera contained 0.17 to 0.24 ng/ml of 
EBER1 (Fig. 4 B), which was sufficient to induce signaling 
from TLR3 (Fig. 2 C). Because we had demonstrated that 
sera nonspecifically induced IFN and cytokines in LCLs, we 
stimulated LCLs with RNA that had been purified from that 
sera. As shown in Fig. 4 C, RNAs from the patient sera, 
which contained a higher amount of EBER1, induced the 
release of IFN- when added to the culture medium of 
LCLs. The quantification of IFN- by ELISA indicated that 
all of the patient sera that we examined induced more IFN- 
(200–ﾭ800 pg/ml) than that induced by the sera from healthy 
individuals. To confirm that IFN- induction by patient sera 
was mediated thorough TLR3, LCLs were pretreated with 
an anti-TLR3 antibody and treated with RNA from a patient 
serum with IM. The results demonstrate that there was a 
marked reduction in the RNA-induced release of IFN- 
(Fig. 4 D), indicating that the RNA from serum induced the 
expression of IFN through TLR3. We also examined whether 
RNAs from the patient sera could induce type I IFN and 
proinflammatory cytokines such as IFN- and TNF in 
PBMCs. As shown in Fig. 4 E, RNAs purified from CAEBV, 
which contained a high level of EBER1, induced the expres-
sion of IFN-, IFN-, and TNF.
EBER1 induces mature surface phenotype and antigen-
presenting capacity of DCs
Finally, we investigated the effect of EBER1 on DC function 
to clarify whether EBER1-mediated signaling is sufficient for 
induction of immune responses. We treated immature DCs 
with EBER1 or poly(I:C) for 24 h and analyzed the surface 
markers of matured DC by flow cytometry. Treatment with 
EBER1, as well as poly(I:C), resulted in an increase of CD83 
and CD86 levels, indicating that EBER1 induces maturation 
of DCs (Fig. 5 A). Because CD86 up-regulation by EBER1 
was clearly reduced by TLR3 siRNA, EBER1-mediated DC 
maturation is dependent on TLR3 (Fig. 5 B). We next inves-
tigated cytokine production by DCs in response to EBER1. 
As shown in Fig. 5 C, IFN- and IL-12 production by DCs 
was induced by EBER1, indicating EBER1-mediated activa-
tion of DCs. Furthermore, sera from patients containing a 
high level of EBER1 induced IL-12 production by DCs in a 
TLR3-dependent manner, whereas sera containing a low 
level of EBER1 or EBV-negative sera could not, suggesting 
that EBER1 in sera is stimulatory for DCs through TLR3 
signaling (Fig. 5 D). To assess whether DCs with maturation 
induced via EBER1 have the capacity of antigen presenta-
tion, DCs treated with EBER1 or poly(I:C) were used for allo 
MLR assay. The stimulatory properties of EBER1- or poly 
(I:C)-treated DCs were compared with those of untreated 
immature DCs. As shown in Fig. 5 E, EBER1- or poly(I:C)-
treated DCs induced comparable allo mixed lymphocyte 
reactions that were most markedly seen with 10,000 DCs/
wells, in a 1:10 stimulator/responder ratios. Therefore, 
from culture supernatants of EBV-positive or EBER-knock-
out EBV-infected cells for stimulation. EBV-positive and 
EBER-knockout EBV-infected AGS cells were transfected 
with Flag-La, and immunoprecipitates from culture superna-
tants were added into a culture medium of EBER-knockout 
EBV-infected AGS cells. As shown in Fig. 3 C, IFN- was 
clearly induced by treatment with immunoprecipitates from 
culture supernatants of EBV-positive cells, whereas the IFN 
induction was reduced by TLR3 knockdown. In contrast, no 
IFN induction was observed in the cells treated with immuno-
precipitates  from  culture  supernatants  of  EBER-knockout 
EBV-infected cells. These results suggest that EBER1 can in-
duce TLR3 signaling in complexes with La.
EBER1 exists in sera from patients with active EBV 
infections and induces the production of type I IFN  
and inflammatory cytokines
Subsequently, we examined the presence of EBER1 in the 
sera of patients with acute EBV infections, such as IM, CAEBV, 
and EBV-HLH. We also investigated the role of EBER on 
the activation of TLR3. Results from RT-PCR assays re-
vealed that EBER1 was detected in patient sera and also in 
Figure 3.  EBER is detected as a complex with La in the culture 
supernatants and the complex is stimulatory for TLR3. (A) Detection 
of La, L22, and PKR in culture supernatants. Mutu+ cells (1 × 106) were 
transfected with Flag-tagged La, L22, or PKR plasmid and cultured for  
48 h. Flag-tagged La, L22, and PKR were detected by immunoblotting of 
the cell lysates (top) and immunoprecipitation of culture supernatants 
(bottom) using an anti-Flag antibody. Three or more independent experi-
ments were performed for each assay. (B) Detection of EBER1 in the 
immunoprecipitates. RNA was extracted from the immunoprecipitates and 
subjected to 30 cycles of RT-PCR to detect EBER1. Three independent 
experiments were performed. (C) Effect of immunoprecipitates from cul-
ture supernatants on IFN- induction. EBER-positive (EBER+) or EBER-
knockout (EBER) EBV-infected AGS cells were transfected with control 
(control) or Flag-tagged La plasmid (Flag La) and cultured for 48 h, fol-
lowed by immunoprecipitation of culture supernatants using anti-Flag 
antibody. Both EBER and EBER+ immunoprecipitates were added into 
the media of EBER-knockout EBV-infected AGS cells transfected with 
negative control siRNA (Flag La+nc) or TLR3 siRNA (Flag La+TLR3si), and 
IFN- induction was analyzed by RT-PCR. The data presented are repre-
sentative of three independent experiments.JEM VOL. 206, September 28, 2009  2095
BRIEF DEFINITIVE REPORT
Figure 4.  EBER1 exists in sera from patients with active EBV infections and induces the production of type I IFN and inflammatory cyto-
kines. (A) Detection of EBER1 by RT-PCR in patient sera. RNA was extracted from 100 µl sera or plasma from patients with IM, CAEBV, and EBV-HLH, and 
from EBV-positive and –negative healthy donors. EBER1 was detected by 35 cycles of RT-PCR. Sample numbers in A–C correspond to each other; samples 
that are followed by a number in an open circle contain higher amounts of EBER1 than those with a number alone. Three or more independent experi-
ments were performed. (B) Quantification of EBER1 in patient sera. RNA was extracted from the sera and subjected to real-time RT-PCR to detect EBER1. 
Error bars indicate the SD of duplicate wells. The data presented are representative of three independent experiments. (C) Induction of IFN- production 
by RNA extracted from patient sera. LCLs (4 × 105) were treated with RNA that had been extracted from 100 µl sera in 1 ml culture medium, incubated for 
14 h, and subjected to 30 cycles of RT-PCR to detect IFN- (left) or ELISA of the culture supernatants for detection of IFN- (right). The data of ELISA are 
shown as the means ± SD of duplicate determination and representative results of three independent experiments are shown. (D) Effect of an anti-TLR3 
antibody on serum-induced IFN- production. LCLs (4 × 105) were preincubated with the anti-TLR3 antibody for 30 min at 37°C, before being treated 
with RNA extracted from 100 µl of serum from a patient with IM or 1.0 µg in vitro–synthesized EBER1 as a positive control in 1 ml culture medium, and 
cultured for 14 h. Production of IFN- was determined by ELISA of the culture supernatants. Error bars indicate the S.D. of duplicate wells. The data pre-
sented are representative of three independent experiments. (E) Effect of the RNA from patients sera on the induction of IFN- and proinflammatory 
cytokines. Human PBMCs (1 × 106) were treated with RNA extracted from 100 µl patients sera or 0.5 µg in vitro–synthesized EBER1 in 1 ml culture me-
dium and cultured for 14 h. The induction of IFN- and proinflammatory cytokines was determined by 30 cycles of RT-PCR. Three independent experi-
ments were performed.2096 TLR3 ACTIVATION BY EBV- ENCODED SMALL RNA | Iwakiri et al.
EBER1-treated DCs were potent inducers of primary allo   
T cell responses.
In this study, we have demonstrated that EBER1 is re-
leased from EBV-infected cells and activates signaling from 
the TLR3. We have also demonstrated that sera from patients 
with active EBV infections such as IM, CAEBV, and EBV-
HLH contained a large amount of EBER1, which was suffi-
cient to activate TLR3 signaling, subsequently resulting in 
the induction of type I IFN and proinflammatory cytokines. 
Furthermore, EBER1-treated DCs could induce primary 
immune response, suggesting that during active infection, 
EBER1-mediated TLR3 stimulation is responsible for im-
mune activation by EBV. TLR3 is predominantly expressed 
on DCs (Doyle et al., 2003; Akira and Takeda, 2004); circu-
lating EBER1 could induce the activation of DCs and subse-
quent T cell activation, leading to the systemic production of 
proinflammatory cytokines. EBER1-mediated immune re-
sponse would be needed for host defense, therefore IM, which 
is characterized as a CTL response against polyclonal prolif-
eration of EBV-infected B cells usually follows a self-limited 
course. In EBV-HLH, EBV-infected cells are mainly CD8+ 
T cells, whereas CD4+ T or NK cells are infected in CAEBV 
(Kasahara et al., 2001). Given that CD8+ T cells and NK cells 
express TLR3 and are activated by TLR3 signals (Schmidt   
et al., 2004; Tabiasco et al., 2006), TLR3-expressing T cells and 
NK cells could be activated by EBER1 through TLR3 and 
produce proinflammatory cytokines. Our findings suggest that 
immunopathologic diseases that are caused by active EBV in-
fections could be attributed to TLR3-mediated cytokinemia 
Figure 5.  EBER1 induces maturation of DC and subsequent anti-
gen presentation. (A) Effect of EBER1 on phenotype of DCs. DCs were 
prepared from PBMCs and untreated or treated with either poly(I:C)  
(10 µg/ml) or EBER1 (10 µg/ml). Surface markers of matured DCs, CD83, and 
CD86 were measured by flow cytometry. As negative control, cells were 
stained with mouse IgG. The data are representative of three independent 
experiments. (B) Effect of TLR3 knockdown on EBER1-mediated DC matu-
ration. DCs were transfected with TLR3 siRNA or control siRNA (nc) and 
were stimulated with EBER1. CD86 positivity (%) was analyzed by flow 
cytometry (left). Efficiency of TLR3 silencing was analyzed by RT-PCR 
(right). Data are shown as the means ± SD of duplicate determination and 
representative results of three independent experiments are shown.  
(C) EBER1-induced cytokine production by DCs. DCs were treated with 
EBER1, and IFN- or IL-12p40 production were measured by ELISA. Error 
bars indicate the SD of duplicate wells, and the data presented are repre-
sentative of three independent experiments. (D) Effect of sera from pa-
tients on TLR3-mediated IL-12 production by DCs. DCs were transfected 
with negative control siRNA or TLR3 siRNA (TLR3si) for 48 h, and then 
stimulated with sera from patients with CAEBV containing high amounts 
of EBER1 (CAEBV (1)) and IL-12 production was measured by ELISA. Sera 
form patients with CAEBV containing low amounts of EBER1 (CAEBV4) or 
EBV-negative (EBV()) healthy donor were also used for stimulation. Data 
are shown as the means ± SD of duplicate determination and representa-
tive results of three independent experiments are shown. (E) Allogenic 
MLR. DCs treated with either poly(I:C) or EBER1 were used as stimulator 
cells. Untreated immature DC were also used as stimulator cells. Allogenic 
PBMCs (1 × 105) were used as responder cells in triplicate cultures. Prolif-
eration of alloreactive T cells was determined by cell proliferation assay. 
Data are shown as the means ± SD of triplicate determination and repre-
sentative results of three independent experiments are shown. Statistical 
significance differences between groups were evaluated by Student’s t 
test. ***, P < 0.001.
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poly(I:C) and polymyxin B were purchased from EMD. Anti-CD83 anti-
body and anti-CD86 antibody were obtained from Beckman Coulter and 
Ancell Co., respectively. Human recombinant GM-CSF and IL-4 were pur-
chased from PeproTech.
RNA extraction and RT-PCR. Total RNA was extracted using Trizol 
reagent (Invitrogen) and was treated with DNaseI (Invitrogen). To analyze 
the release of EBER, RNA was extracted from 1 ml culture media or 100 µl 
serum and plasma. Reverse transcription was performed using SuperScript II 
reverse transcription (Invitrogen) and oligo-dT primer (Promega) or se-
quence-specific primers for EBER1 and EBER2. The sequence of the prim-
ers used for PCR was as follows. EBER1 (5-AGGACCTACGCTGC-
CCTAGA-3, 5-AAAACATGCGGACCAGC-3), EBER2 (5-AGGGA-
CAGCCGTTGCCCTAGTGGTTTCGGA-3,   5-AAAACAGCGGACA-
AGCCGAATACC-3), TLR3 (5-TCACTTGCTCATTCTCCCTT-3, 
5-GACCTCTCCATTCCTGGC-3),  IFN  (5-GATTCATCGAG-
CACTGGCTGG-3,  5-CTTCAGGTAATGCAGAATCC-3),  IFN- 
(5-CAGGTCATTCAGATGTAGCG-3,  5-GCTTTTCGAAGTCAT-
CTCG-3),  TNF  (5-CTTCTGCCTGCTGCACTTTGGA-3,  5-TCC-
CAAAGTAGACCTGCCCAGA-3),  and  GAPDH  (5-GCCTCCTG-
CACCACCAACTG-3, 5-CGACGCCTGCTTCACCACCTTCT-3).
Quantification of EBER1. EBER1 was prepared by in vitro transcription 
as previously described (Samanta et al., 2006). Serial dilutions of EBER1 
(0.1 ng/ml to 1.0 µg/ml) were made in culture media and total RNA was 
extracted and used for real-time PCR using the LightCycler system (Roche). 
These results were used as a standard for measuring the amount of EBER1 
in culture supernatant.
Analysis of TLR3 activation. In vitro–ﾭsynthesized EBER1 or poly(I:C) 
and RNAs that had been prepared from culture supernatants or human sera 
were mixed with Lipofectamine 2000 (Invitrogen) for 15 min in Opti-MEM 
(Invitrogen) before being used to stimulate the cells. The reagents were in-
cubated in the tissue culture medium for 1 h before being removed by wash-
ing. To neutralize TLR3, cells were pretreated with an anti-TLR3 antibody 
(40 µg/ml) for 30 min at 37°C. The antibody was then removed before the 
TLR3 stimulation.
Measurement of cytokine production. Cell culture supernatants were 
collected and analyzed for IFN- and IL-12 p40 production using a human 
IFN- ELISA kit (PBL Biomedical Laboratories) or OptEIA human IL-12 
(p40) ELISA kit (BD) according to the manufacturer’s protocol.
Immunoblotting. Cells were lysed with 1% NP-40 lysis buffer and the cell 
lysates were subjected to SDS-PAGE and subsequent electrotransfer onto 
nitrocellulose membranes. The membranes were blocked with 5% bovine 
serum albumin (Sigma-Aldrich) or nonfat milk in TBS containing 0.05% 
Tween 20, and were subsequently treated with the primary antibodies for 
phospho-IRF3, IRF-3, phospho-p65, and the Flag tag.
Analysis of EBER-protein interactions by coimmunoprecipitation. 
Mutu cells (2 × 106) were transfected with Flag-La, Flag-L22, and Flag-PKR 
expression plasmids by electroporation. After 48 h, 1 ml culture supernatant 
was harvested and incubated with 3.5 µg anti-Flag mouse monoclonal anti-
body for 14 h at 4°C. After the addition of 50 µl of protein G–ﾭSepharose 
(GE Healthcare), mixtures were incubated at 4°C for 3 h. Sepharose beads 
were pelleted and washed twice with lysis buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, and 20% protease/
inhibitor) and three times with wash buffer (50 mM Tris-HCl, pH 7.4, 200 mM 
NaCl, 0.1% Nonidet P-40, 0.05% deoxycholate, 10% protease/inhibitor 
mix, 100 units/ml RNasin, 0.4% vanadyl ribonucleoside complex, and 
1 mM dithiothreitol) by end-over-end rotation for 10 min. Pellets were dis-
solved in SDS loading buffer and subjected to immunoblotting. For RNA 
extraction, pellets were dissolved in 100 µl of lysis buffer and digested with 
30 µg of proteinase K for 30 min at 50°C with the addition of 0.1% SDS, 
by EBER1, and that circulating EBER1 could be a potential 
target for therapeutic agents. Because it has been reported 
that plasmacytoid DCs are involved in anti-EBV immunity 
by the secretion of IFN and T cell activation through TLR9 
pathways (Lim et al., 2007), TLR3 would collaborate with 
TLR9 during primary EBV infection.
Recent studies have demonstrated that activation of 
TLR3 by viral dsRNA contributes to viral pathogenesis. For 
example, TLR3-mediated inflammatory responses by viral 
dsRNA contribute to the development of lethal encephalitis 
by facilitating virus entry into the brain during West Nile 
virus infection (Wang et al., 2004). Rotavirus genomic dsRNA 
induces severe injury in the small intestine of mice in a TLR3-
dependent manner (Zhou et al., 2007). These findings, along 
with ours, suggest that activation of TLR3 induces not only 
protective effects against viral infection but also effects that 
contribute to viral pathogenesis.
It was reported that EBER1 mostly binds to L22 (Toczyski 
and Steitz, 1993). Therefore, if EBER1 is released because of 
cell death, it would be released with Flag-L22 rather than 
other Flag-tagged proteins from the cell, in which those pro-
teins are equally expressed. However, the majority of the 
EBER1 that was released from the cells existed in a complex 
with Flag-La, whereas other EBER-binding proteins, such as 
PKR and L22 were faintly detected. This led us to hypothe-
size that EBER1 is released from the cells by active secretion 
of La. Because La has been reported to be secreted as an exo-
some (Kapsogeorgou et al., 2005), EBER1 might also be se-
creted in this manner by binding to La. Alternatively, if La is 
more stable than L22 in extracellular state, EBER1 released 
by cell death could be strongly detected with La. Interest-
ingly, we also demonstrated that EBER1 stimulates TLR3 in 
complexes with La protein. Further study is needed to clarify 
how the EBER1–ﾭprotein complex is recognized by TLR3 
and the mechanism of EBER1 release.
In contrast to EBER1, EBER2 was faintly detected in the 
culture supernatants of EBV-infected cells or in sera from pa-
tients with active EBV infections. EBER2 has a shorter half-life 
than EBER1, which may account for the preferential detection 
of EBER1 in our experiments (Clarke et al., 1992).
MATERIALS AND METHODS
Cell culture and reagents. LCLs, the EBV-positive Burkitt’s lymphoma 
cell lines Akata+ (Takada, 1984) and Mutu+ (Gregory et al., 1990), and the 
EBV-negative cell lines Akata (Shimizu et al., 1994) and Mutu (Nanbo 
et al., 2002) were cultured in RPMI 1640 media (Sigma-Aldrich) supple-
mented with 10% FBS (Invitrogen) and antibiotics. Akata cells that had 
been reinfected with recombinant EBER-positive EBV (Akata/EBER+EBV; 
Shimizu et al., 1996) or EBER-knockout EBV (Akata/EBEREBV; Yajima 
et al., 2005) were cultured in RPMI 1640 media containing 700 µg/ml 
G418 (Sigma-Aldrich). EBV-infected (EBV+) and neomycin-resistant gene 
transfected (EBV) NU-GC-3 cells and EBER-positive EBV or EBER-
knockout EBV-infected AGS cells were cultured in Dulbecco’s modified 
Eagle’s medium (Sigma-Aldrich) supplemented with 10% FBS, antibiotics, 
and 500 µg/ml G418. The anti-Flag antibody and mouse IgG1 were pur-
chased from Sigma-Aldrich. The anti-TLR3 antibody was obtained from 
eBioscience, and the anti-phospho IRF3 antibody, anti-IRF3 antibody, and 
anti-phospho p65 antibody were obtained from Cell Signaling Technology. 2098 TLR3 ACTIVATION BY EBV- ENCODED SMALL RNA | Iwakiri et al.
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before being dissolved in Trizol reagent. Extracted RNA was analyzed by 
RT-PCR for the expression of EBER1.
Flow cytometry. Cells were washed with FACS buffer (PBS containing 
0.1% BSA, 0.1% NaN3) and stained with anti-CD83 antibody (1 µg), anti-
CD86 antibody (0.5 µg), or mouse IgG1 (1 µg) together with human IgG 
(10 µg) for 30 min at 4°C. After washing twice with FACS buffer, cells were 
incubated with FITC-labeled secondary antibody (American Qualex) for 
30 min at 4°C, and then analyzed on a FACSCalibur (BD).
Preparation and stimulation of DCs. The institutional committee at 
Hokkaido University approved the use of human blood samples for this 
study. CD14+ monocytes were isolated from human PBMC using a MACS 
system (Miltenyi Biotec). Immature DCs were generated from monocytes 
by culture for 6 d in RPMI 1640 medium supplemented with 10% heat- 
inactivated FCS (SAFC Biosciences) in the presence of 500 IU/ml recombi-
nant human GM-CSF and 100 IU/ml recombinant human IL-4. Immature 
DCs (106 cells/ml) were treated with poly(I:C) (10 µg/ ml) or synthesized 
EBER1 (10 µg/ml) for 24 h. Both reagents were treated with polymyxin B 
(5 µg/ml) at 37°C for 1 h before stimulation.
TLR3  knockdown  experiment.  TLR3  stealth  RNAi  (Invitrogen)  or 
stealth  RNAi  negative  control  (Invitrogen)  was  transfected  using  Lipo-
fectamine RNAiMAX (Invitrogen) according to the manufacturer’s proto-
col. Successful transfection was confirmed using the BLOCK-iT Alexa Fluor 
Red Fluorescent Oligo (Invitrogen). Monocytes were cultured for 4 d be-
fore being transfected (106 cells/well, 24 well plate) on day 4 and again on 
day 5 with 70 nM siRNA. On day 6 (48 h after the first transfection), cells 
were used for stimulation. AGS cells (105 cells/well, 24-well plate) were 
transfected with 10 nM siRNAs and used for stimulation after 48 h.
Mixed lymphocyte reaction (MLR) assay. After 24 h stimulation with 
poly(I:C)  or  EBER1,  DCs  were  treated  with  50  µg/ml  mitomycin  C 
(MMC). Allo-PBMC were isolated by Histopaque density gradient separa-
tion of blood collected from healthy donors. Serial dilutions (104 to 103 
cells/well) of MMC-treated DCs were cultured in triplicate with 105 PBMCs 
in 96-well round-bottom plates for 3 d, and PBMC proliferation was 
measured  using  CellTiter  96  nonradioactive  cell  proliferation  assay   
kit (Promega).
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